Changing Treatment Paradigm of Type 2 Diabetes.
作者信息
Hur Kyung Yul
机构信息
Department of Surgery, Soonchunhyang University Hospital, Seoul, Korea.
出版信息
J Minim Invasive Surg. 2020 Sep 15;23(3):107-109. doi: 10.7602/jmis.2020.23.3.107.
Abstract
摘要
相似文献
1
Changing Treatment Paradigm of Type 2 Diabetes.
J Minim Invasive Surg. 2020 Sep 15;23(3):107-109. doi: 10.7602/jmis.2020.23.3.107.
2
[Changing paradigm in the management of type 2 diabetes Changing paradigm in the management of type 2 diabetes Changing paradigm in the management of type 2 diabetes Changing paradigm in the management of type 2 diabetes Changing paradigm in the management of type 2 diabetes].
Ceylon Med J. 2022 Sep 30;67(3):71-74. doi: 10.4038/cmj.v67i3.9706.
3
Changing the diabetes treatment paradigm.
Arch Intern Med. 2009 Jul 13;169(13):1246; author reply 1247. doi: 10.1001/archinternmed.2009.185.
4
Insulin is necessary but not sufficient: changing the therapeutic paradigm in type 1 diabetes.
F1000Res. 2020 Jul 30;9. doi: 10.12688/f1000research.21801.1. eCollection 2020.
5
Changing the treatment paradigm for type 2 diabetes.
Diabetes Care. 2009 Nov;32 Suppl 2(Suppl 2):S217-22. doi: 10.2337/dc09-S314.
6
Future challenges and therapeutic opportunities in type 2 diabetes: Changing the paradigm of current therapy.
Diabetes Obes Metab. 2017 Oct;19(10):1339-1352. doi: 10.1111/dom.12977. Epub 2017 Jun 9.
7
Combination therapy as a first step of treatment in diabetes: Changing the paradigm in KDIGO guidelines?
Eur J Intern Med. 2023 May;111:21-23. doi: 10.1016/j.ejim.2023.02.024. Epub 2023 Mar 15.
8
Type 2 diabetes - unmet need, unresolved pathogenesis, mTORC1-centric paradigm.
Rev Endocr Metab Disord. 2020 Dec;21(4):613-629. doi: 10.1007/s11154-020-09545-w.
9
SGLT2 inhibitors and the changing landscape for treatment of diabetes.
Ther Clin Risk Manag. 2019 Jul 9;15:861-867. doi: 10.2147/TCRM.S207515. eCollection 2019.
10
Changing the Concept: From the Traditional Glucose-centric to the New Cardiorenal-metabolic Approach for the Treatment of Type 2 Diabetes.
touchREV Endocrinol. 2021 Nov;17(2):92-101. doi: 10.17925/EE.2021.17.2.92. Epub 2021 Nov 17.
本文引用的文献
1
Metabolic Outcomes of Surgery for Non-Obese Type 2 Diabetes.
J Minim Invasive Surg. 2020 Jun 15;23(2):57-62. doi: 10.7602/jmis.2020.23.2.57.
2
The early history of GIP 1969-2000: From enterogastrone to major metabolic hormone.
Peptides. 2019 Dec;122:170155. doi: 10.1016/j.peptides.2019.170155. Epub 2019 Sep 17.
3
The evolution of cancer surgery and future perspectives.
Nat Rev Clin Oncol. 2015 Feb;12(2):115-24. doi: 10.1038/nrclinonc.2014.191. Epub 2014 Nov 11.
4
Short-term outcomes of laparoscopic single anastomosis gastric bypass (LSAGB) for the treatment of type 2 diabetes in lower BMI (<30 kg/m(2)) patients.
Obes Surg. 2014 Jul;24(7):1044-51. doi: 10.1007/s11695-014-1202-5.
5
Incretin levels 1 month after laparoscopic single anastomosis gastric bypass surgery in non-morbid obese type 2 diabetes patients.
Asian J Surg. 2014 Jul;37(3):130-7. doi: 10.1016/j.asjsur.2013.09.008. Epub 2013 Nov 6.
6
The big fat bariatric bandwagon.
Diabetologia. 2010 Sep;53(9):1815-22. doi: 10.1007/s00125-010-1845-2.
7
Effect of duodenal-jejunal exclusion in a non-obese animal model of type 2 diabetes: a new perspective for an old disease.
Ann Surg. 2004 Aug;240(2):388-9; author reply 389-91. doi: 10.1097/01.sla.0000134632.08789.df.
Zotero 插件